News
2024 Press Releases
Humanetics Corporation Presents at the 2024 Department of Defense Scientific Meeting
Humanetics to Participate in the BIO Investor Forum in San Francisco
Uniformed Services University Awards Grant To Support Continued Collaboration with Humanetics to Develop Radiation Countermeasure
Humanetics to Present at the Biotechnology Innovation Organization (BIO) International Convention
Humanetics to Present at Investor and Partner Conferences
2023 Press Releases
Major General (Ret.) Barbara R. Holcomb Joins Board at Humanetics
Humanetics Corporation Appoints Dr. Colin Chinn as Chief Medical Officer
Humanetics Corporation Receives Funding to Study New Drug for Idiopathic Pulmonary Fibrosis
Humanetics Corporation Publishes Clinical Trial Results of BIO 300 in Patients with NSCLC
Humanetics Corporation Awarded Contract from Department of Defense to Develop First FDA Approved Drug to Prevent Radiation Injury
BIO 300 Featured at the 2023 Military Health System Research Symposium
BIO 300 Enhances Radiotherapy Efficacy Against Lung Tumors in a NonClinical Model
Humanetics Announces Positive Results from Independent Data Monitoring Committee
BIO 300 Demonstrates Protection Against Radiation-Induced Lung Injury
2022 Press Releases
Humanetics Corporation Presents at the MedInvest Oncology Investor Conference
Humanetics Corporation Publishes Results of Phase 1 Study of BIO 300 Oral Powder
Humanetics Corporation Presents at the 2022 Annual Radiation Research Society Meeting
FDA Clears BIO 300 Studies in Second Oncology Indication
Thomas F. Jasper Joins Board at Humanetics
Jake R. Nunn Joins Board at Humanetics
BIO 300 Pharmacokinetics Studies Published
US Department of Defense Awards $5.1 Million to Humanetics for Continued Development of Radiation Countermeasure
Humanetics Expands Clinical Sites for Long-Haul COVID-19 Trial
New Data Published Comparing BIO 300 with Neulasta
Humanetics Corporation Appoints Mr. Douglas W. Bryce to its Board of Advisors
2021 Press Releases
Humanetics Corporation Adds Two New Board Members
Humanetics Corporation Completes Phase 1 Trial
Humanetics Corporation's BIO 300 Receives FDA Fast Track Designation
Humanetics Receives Funding to Study New Drug for Triple Negative Lung Cancer
Humanetics Receives Funding from Department of Defense for COVID-19 Studies
2020 Press Releases
Humanetics Presents New Data at Radiation Research Society Meeting
Matthew L. Nathan, M.D., Former Surgeon General of the U.S. Navy, Joins Board of Directors
NIAID to Fund Clinical Trial of BIO 300 in COVID-19 Patients
Humanetics Invited for Oral Presentation at ASTRO
Dr. Colin Chinn, Former Joint Staff Surgeon, Joins Humanetics Medical Advisory Board
Humanetics Acquires Assets for Radioprotectant Drug
2019 Press Releases
U.S DEPARTMENT OF DEFENSE AWARDS $6 MILLION TO HUMANETICS CORPORATION FOR ADVANCED DEVELOPMENT OF RADIOPROTECTANT
2018 Press Releases
Humanetics to Present at the Annual Meeting of the American Society for Radiation Oncology
Humanetics Corporation Invited to Present Data on BIO 300 at Government Conference
Humanetics Presents Data on New Drug to Prevent Radiation Injury
Humanetics Awarded Patent for Oral Drug to Protect Warfighters and First Responders from Radiation Exposure
Humanetics Awarded Federal Contract to Develop New Radiation Countermeasure to Protect the Lungs
Humanetics Corporation Presents at BIO CEO and Investor Conference
Humanetics Corporation Presents Data on Drug to Protect Cardiac Cells Against Toxicity from Space-like Radiation
Vice Admiral Matthew L. Nathan, M.D., Former Surgeon General of the U.S. Navy, Joins Humanetics' Medical Advisory Board
2017 Press Releases
Humanetics Presents Data on BIO 300
Humanetics Receives Grant From NASA
Humanetics Received $3.8 Million Grant from Department of Defense
Humanetics Awarded Patent for BIO 300
Humanetics to Present at Department of Defense Scientific Meeting
Humanetics Awarded Patent to Mitigate Erectile Dysfunction Associated with Prostate Cancer Radiotherapy
2016 Press Releases
Humanetics Received New Federal Grant to Continue Development of Radiation Countermeasure
Space Institute to Fund Testing of Radiation Protectants
2015 Press Releases
Humanetics Corporation Granted FDA Clearance To Proceed With Cancer Treatment Study
2014 Press Releases
New Grant Enables Humanetics Corporation to Evaluate Potential Treatment for Erectile Dysfunction in Prostate Cancer Patients
Humanetics Corporation Enters Into Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Chemical Defense
Humanetics Corporation Granted Approval by the National Cancer Institute to Proceed with Cancer Treatment Study
2013 Press Releases
Humanetics Corporation Awarded Patent Enabling Oral Administration of Powerful Radioprotectant
2012 Press Releases
Humanetics Awarded Contract With National Cancer Institute